A Nomogram to Identify the Optimal Candidates for Induction Chemotherapy in Advanced N-Stage Nasopharyngeal Carcinoma

References

• Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. doi:10.1186/s40880-017-0257-9
   PubMedGoogle Scholar
• Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group Phase II trial 0225. J Clin Oncol. 2009;27(22):3684–3690. doi:10.1200/JCO.2008.19.9109
   PubMed Web of Science ®Google Scholar
• Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403. doi:10.1016/j.radonc.2013.10.020
   PubMed Web of Science ®Google Scholar
• Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65(1):161–168. doi:10.1016/j.ijrobp.2005.12.003
   PubMed Web of Science ®Google Scholar
• Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–1334. doi:10.1016/j.ijrobp.2008.07.062
   PubMed Web of Science ®Google Scholar
• Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(4):546–558. doi:10.1002/cncr.29795
   PubMed Web of Science ®Google Scholar
• Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23. doi:10.1016/j.ejca.2016.12.039
   PubMed Web of Science ®Google Scholar
• Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–736. doi:10.1093/annonc/mdx770
   PubMed Web of Science ®Google Scholar
• Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–249. doi:10.1200/JCO.2008.18.1545
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Peng H, Dong D, Fang MJ, et al. Prognostic value of deep learning PET/CT-based radiomics: potential role for future individual induction chemotherapy in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2019;25(14):4271–4279. doi:10.1158/1078-0432.CCR-18-3065
   PubMed Web of Science ®Google Scholar
• Sun XS, Xiao BB, Lu ZJ, et al. Stratification of candidates for induction chemotherapy in stage III-IV nasopharyngeal carcinoma: a large cohort study based on a comprehensive prognostic model. Front Oncol. 2020;10:255. doi:10.3389/fonc.2020.00255
   PubMed Web of Science ®Google Scholar
• Xie HJ, Yu YF, Sun XS, et al. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [(18) F]-fluorodeoxyglucose positron emission tomography. Cancer Med. 2020;9(23):8852–8863. doi:10.1002/cam4.3500
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Mao YP, Tang LL, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer. 2016;35(1):103. doi:10.1186/s40880-016-0167-2
   PubMedGoogle Scholar
• Peng H, Chen L, Li WF, et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis. Oral Oncol. 2016;62:78–84. doi:10.1016/j.oraloncology.2016.10.014
   PubMed Web of Science ®Google Scholar
• Wei J, Feng H, Xiao W, et al. Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma. Chin J Cancer Res. 2018;30(1):51–60. doi:10.21147/j.issn.1000-9604.2018.01.06
   PubMed Web of Science ®Google Scholar
• Ai QY, King AD, Poon DMC, et al. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncol. 2019;88:124–130. doi:10.1016/j.oraloncology.2018.11.007
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang Y, Liu Y, et al. Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system. Radiother Oncol. 2019;140:90–97. doi:10.1016/j.radonc.2019.04.024
   PubMed Web of Science ®Google Scholar
• Wan Y, Tian L, Zhang G, et al. The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy. Radiother Oncol. 2019;131:35–44. doi:10.1016/j.radonc.2018.11.001
   PubMed Web of Science ®Google Scholar
• Dong D, Zhang F, Zhong LZ, et al. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). BMC Med. 2019;17(1):190. doi:10.1186/s12916-019-1422-6
   PubMed Web of Science ®Google Scholar
• Luo WJ, Zou WQ, Liang SB, et al. Combining tumor response and personalized risk assessment: potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Radiother Oncol. 2021;155:56–64. doi:10.1016/j.radonc.2020.10.005
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Liu X, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107. doi:10.1016/j.oraloncology.2017.04.015
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–1135. doi:10.1056/NEJMoa1905287
   PubMed Web of Science ®Google Scholar
• Lan XW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. 2017;10:3853–3860. doi:10.2147/OTT.S133917
   PubMed Web of Science ®Google Scholar
• Li P, Zhang Q, Luo D, et al. Explore the value of adding induction chemotherapy to concurrent chemoradiotherapy in T3-4N0M0 nasopharyngeal carcinoma patients: a retrospective study. Cancer Manag Res. 2021;13:7067–7076. doi:10.2147/CMAR.S321471
   PubMed Web of Science ®Google Scholar
• Wang L, Wu Z, Xie D, Lv S, Xia L, Su Y. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis. Radiat Oncol. 2020;15(1):160. doi:10.1186/s13014-020-01594-4
   PubMed Web of Science ®Google Scholar
• Wu LR, Yu HL, Jiang N, et al. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017;8(44):76807–76815. doi:10.18632/oncotarget.20014
   PubMedGoogle Scholar
• Liu K, Lin S, Ke L, et al. Prognostic value and the potential role of treatment options for cervical lymph node necrosis in nasopharyngeal carcinoma. Oral Oncol. 2020;109:104864. doi:10.1016/j.oraloncology.2020.104864
   PubMed Web of Science ®Google Scholar
• Chen YP, Mao YP, Zhang WN, et al. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis. Oncotarget. 2016;7(12):14973–14982. doi:10.18632/oncotarget.7789
   PubMedGoogle Scholar
• Jiang YT, Chen KH, Yang J, et al. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2022;44(5):1182–1191. doi:10.1002/hed.27011
   PubMed Web of Science ®Google Scholar
• Liang H, Xiang YQ, Lv X, et al. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. Eur J Cancer. 2017;73:48–60. doi:10.1016/j.ejca.2016.12.009
   PubMed Web of Science ®Google Scholar
• Yang K, Tian J, Zhang B, et al. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2019;98:85–91. doi:10.1016/j.oraloncology.2019.09.022
   PubMed Web of Science ®Google Scholar